Skip to Content
  • Previous Rank54
  • Revenues ($M)$52,546.00
  • Revenue Percent Change-0.5%
  • Profits ($M)$21,308.00
  • Profits Percent Change195.3%
  • Assets ($M)$171,797.00
  • Employees90,200
  • Market Value — as of March 29, 2018 ($M)$211,115.30

Last year marked the end of an era for Pfizer. As the company’s patent exclusivity expired for Viagra, its blockbuster erectile dysfunction drug, the pharmaceutical giant has struggled to discover its next big hit. In January, Pfizer discontinued its research into treatments for Alzheimer’s and Parkinson’s. And after long resisting calls to split itself up, the company is now mulling whether to sell its consumer healthcare business to suitors such as Procter & Gamble. Meanwhile Pfizer, which acquired biosimilars maker Hospira in 2015, is still working to address that company’s manufacturing issues, which have led to drug shortages.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Ian C. Read
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York City
Websitehttp://www.pfizer.com
Years on Fortune 500 List24
Employees90,200

Pfizer Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$52,546.00-0.5%
Profits ($M)$21,308.00195.3%
Assets ($M)$171,797.00-
Total Stockholder Equity ($M)$71,308.00-
Market Value — as of March 29, 2018 ($M)$211,115.30-

Profit Ratios

Profit as % of Revenues40.6%
Profits as % of Assets12.4%
Profits as % of Stockholder Equity29.9%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)3.52
EPS % Change (from 2016)200.9%
EPS % Change (5 year annual rate)12.7%
EPS % Change (10 year annual rate)11.6%

Total Return

Total Return to Investors (2017)15.7%
Total Return to Investors (5 year, annualized)11.4%
Total Return to Investors (10 year, annualized)9.3%